Drug intelligence / Profile preview

lidocaine hydrochloride + dextrose

Development stage
Approved
Modality
Device-based Delivery → Drug Delivery Systems
Administration
Intravenous, Intrathecal
01

Overview

Lidocaine hydrochloride + dextrose is a combination medication available in different formulations for specific medical uses. It consists of lidocaine hydrochloride (an amide-type local anesthetic and antiarrhythmic agent) combined with dextrose in a sterile solution. The medication comes in two main formulations: 1. For intravenous use (0.4% or 0.8% lidocaine with 5% dextrose) - used as a cardiac antiarrhythmic agent[1][9] 2. For spinal anesthesia (5% lidocaine with 7.5% dextrose) - used as a hyperbaric solution for spinal anesthesia[2][5] ## Intravenous Formulation The intravenous formulation is specifically indicated for: - Acute management of ventricular arrhythmias during cardiac manipulations (such as cardiac surgery) - Life-threatening arrhythmias of ventricular origin (such as during acute myocardial infarction)[1][3] The onset of action after intravenous injection is rapid (45-90 seconds), with a duration of action of 10-20 minutes[4]. For continuous infusion, the medication is typically administered at a rate of 1-4 mg/min for adults (20-50 mcg/kg/min)[1][9]. ## Spinal Anesthesia Formulation The spinal anesthesia formulation (5% lidocaine with 7.5% dextrose) is a hyperbaric solution used for spinal anesthesia[2][5]. The duration of perineal anesthesia provided by 1 mL (50 mg) averages 100 minutes, with analgesia continuing for an additional 40 minutes. For surgical anesthesia, 1.5 to 2 mL (75 to 100 mg) provides approximately two hours of anesthesia[5]. ## Mechanism of Action Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action[2][5]. For cardiac arrhythmias, lidocaine's mode of action appears similar to procaine, procainamide, and quinidine. It depresses ventricular excitability and increases the stimulation threshold of the ventricle during diastole, while the sinoatrial node remains unaffected[4]. ## Contraindications The medication is contraindicated in: - Patients with known hypersensitivity to local anesthetics of the amide type - Patients with Stokes-Adams syndrome, Wolff-Parkinson-White syndrome - Patients with severe degrees of sinoatrial, atrioventricular, or intraventricular block - Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products[1][3] ## Administration and Dosage For intravenous use, constant monitoring with an electrocardiograph is essential. The medication should only be administered with a calibrated infusion device[3][9]. For spinal anesthesia, the solution may be administered in the right or left lateral recumbent or sitting position, and the patient can be positioned according to surgical requirements after the anesthetic has become fixed (usually 5-10 minutes)[5]. ## Pharmacokinetics Lidocaine is completely absorbed following parenteral administration. The elimination half-life following an intravenous bolus injection is typically 1.5 to 2.0 hours. This half-life may be prolonged two-fold or more in patients with liver dysfunction. In patients with severe renal dysfunction, lidocaine clearance is decreased by half[6]. Pharmacokinetic data indicate reduced elimination of lidocaine after prolonged infusion (24 hours) with resultant prolongation of the half-life to approximately three times that seen following a single administration[1][9].

Brand names
Lidocaine Hydrochloride and Dextrose Injection
Other names
lidocaine and dextroselidocaine hydrochloride and dextrose injectionlidocaine hydrochloride and 5% dextrose injection
02

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on lidocaine hydrochloride + dextrose.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lidocaine hydrochloride + dextrose.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call